| Name | Title | Contact Details |
|---|
Venture Technology Group is a Farmington Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Curve™ Spine Frame The KYRA Curve has a class-...
As the leading provider of targeted drug delivery (TDD) and infusion care, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected across our two divisions. ● A center of excellence in high-risk intrathecal compounding, AIS Healthcare Targeted Drug Delivery prepares and ships more than 140,000 patient-specific dispenses annually to all 50 states. We also offer comprehensive care services to support patients and empower providers, including in-home pump care and care coordination services. ● At Advanced Infusion Care, we provide high-quality intravenous (IV) and subcutaneous (SubQ) immunoglobulin therapies and in-home care to more than 1,500 patients across the country. Our nationally accredited home infusion team, including infusion nurse specialists and clinical pharmacists, partner closely with physicians to provide the best possible infusion care. AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.
Greater Nashua Mental Health believes in empowering people to lead full and satisfying lives through effective treatment and support.